Janet Warrington Consulting

Voice: 650.400.1795

Senior executive with broad innovation experience and talent for advancing novel biotechnologies and medical devices to market. Drives new initiatives from concept through implementation. Demonstrated success building and leading large, diverse groups to achieve challenging goals with mutually beneficial outcomes. Superb ability to communicate complex information and knowledge to scientific, regulatory, investment communities as well as the general public. Fundraising capabilities, generated more than $75M in public and private capital.

Background

With more than twenty-five years of experience in genetics, biotechnology, and molecular diagnostics, my focus is on moving new technologies and applications into clinical practice. As Co-founder and Senior Vice President, Second Genome Inc., led strategic planning and implementation of technology solutions for internal R&D as well as commercial research service offerings. Raised $1.2 M in seed funding and was responsible for premarket development, laboratory operations, establishing comprehensive pre-analytic and analytic microbial profiling protocols and standard operating procedures for life sciences applications. Initiated microbiome discovery platform for identification of therapeutic targets and oversaw operations of multiple laboratories and clinical trials with key commercial and academic partners. Led microbiome signature discovery in gut health. As an early employee of Affymetrix Inc., I helped build the company from a small start-up to a multi-billion dollar market cap corporation, serving in a variety of roles including Vice President of Research and Development for Emerging Markets and Molecular Diagnostics. In partnership with Roche Molecular Systems, I was the originator and lead scientist for the first FDA cleared microarray system for a diagnostic test. My work has resulted in over 75 publications and patents. As founder and chair-holder of the External RNA Controls Consortium (ERCC), I led an international group of scientists from both public and private sectors to establish the first panel of nucleic acid Standard Reference Material at the National Institute of Standards and Technology (NIST). I had the privilege of serving as a member of the Personalized Healthcare Working Group, American Health Information Community (AHIC), U.S. Department of Health and Human Services (HHS) as well as chairing the Subcommittees on Genetic and Genomic Tests and Pharmacogenomics. I also served as a business and industry council (BIAC) member to the Organization of Economic Cooperation and Development (OECD) Biotechnology Working Group.

Clients

My clients include large and small domestic and international biotechnology and diagnostic companies as well as government agencies and institutions.

health